Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GE HealthCare Technologies (GEHC) Capital Expenditures (2022 - 2025)

Historic Capital Expenditures for GE HealthCare Technologies (GEHC) over the last 4 years, with Q4 2025 value amounting to $134.0 million.

  • GE HealthCare Technologies' Capital Expenditures rose 3137.25% to $134.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $482.0 million, marking a year-over-year increase of 2019.95%. This contributed to the annual value of $482.0 million for FY2025, which is 2019.95% up from last year.
  • GE HealthCare Technologies' Capital Expenditures amounted to $134.0 million in Q4 2025, which was up 3137.25% from $110.0 million recorded in Q3 2025.
  • In the past 5 years, GE HealthCare Technologies' Capital Expenditures registered a high of $152.0 million during Q1 2025, and its lowest value of $59.0 million during Q2 2022.
  • In the last 4 years, GE HealthCare Technologies' Capital Expenditures had a median value of $92.0 million in 2023 and averaged $98.8 million.
  • Its Capital Expenditures has fluctuated over the past 5 years, first soared by 4300.0% in 2023, then tumbled by 857.14% in 2024.
  • Quarter analysis of 4 years shows GE HealthCare Technologies' Capital Expenditures stood at $77.0 million in 2022, then rose by 22.08% to $94.0 million in 2023, then rose by 8.51% to $102.0 million in 2024, then surged by 31.37% to $134.0 million in 2025.
  • Its Capital Expenditures was $134.0 million in Q4 2025, compared to $110.0 million in Q3 2025 and $86.0 million in Q2 2025.